50543 Upadacitinib Improves Atopic Dermatitis-Related Nighttime Itch and Reduces Sleep Disturbance: Analysis of Time Spent in Response State From the Integrated Phase 3 Measure Up 1/2 Clinical Trials.

MLA

Blauvelt, Andrew, et al. “50543 Upadacitinib Improves Atopic Dermatitis-Related Nighttime Itch and Reduces Sleep Disturbance: Analysis of Time Spent in Response State From the Integrated Phase 3 Measure Up 1/2 Clinical Trials.” Journal of the American Academy of Dermatology, vol. 91, no. 3, Sept. 2024, p. AB95. EBSCOhost, https://doi.org/10.1016/j.jaad.2024.07.385.

APA

Blauvelt, A., Prajapati, V. H., Ständer, S., Pink, A. E., Herranz-Pinto, P., Yosipovitch, G., Lee, W.-J., Calimlim, B. M., Platt, A. M., & Silverberg, J. I. (2024). 50543 Upadacitinib Improves Atopic Dermatitis-Related Nighttime Itch and Reduces Sleep Disturbance: Analysis of Time Spent in Response State From the Integrated Phase 3 Measure Up 1/2 Clinical Trials. Journal of the American Academy of Dermatology, 91(3), AB95. https://doi.org/10.1016/j.jaad.2024.07.385

Chicago

Blauvelt, Andrew, Vimal H. Prajapati, Sonja Ständer, Andrew E. Pink, Pedro Herranz-Pinto, Gil Yosipovitch, Wan-Ju Lee, Brian M. Calimlim, Andrew M. Platt, and Jonathan I. Silverberg. 2024. “50543 Upadacitinib Improves Atopic Dermatitis-Related Nighttime Itch and Reduces Sleep Disturbance: Analysis of Time Spent in Response State From the Integrated Phase 3 Measure Up 1/2 Clinical Trials.” Journal of the American Academy of Dermatology 91 (3): AB95. doi:10.1016/j.jaad.2024.07.385.